Lymphoid Leukemia
Showing 1 - 25 of 6,227
H19 in Acute Lymphoblastic Leukemia.
Not yet recruiting
- Acute Lymphoid Leukemia
- (no location specified)
Jul 11, 2023
Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality Trial in São Paulo (Prednisone, Vincristin, Daunorubicin)
Recruiting
- Acute Lymphoid Leukemia
- +3 more
- Prednisone
- +9 more
-
São Paulo, SP, BrazilInstituto do Cancer do Estado de Sao Paulo
Jul 24, 2023
Breast Cancer, Hodgkin Lymphoma, Kidney Cancer Trial (Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH)
Not yet recruiting
- Breast Cancer
- +9 more
- Assessment tool IA3-CP with SDoH
- Assessment tool IA3-CP without SDoH
- (no location specified)
May 22, 2023
Acute Lymphoid Leukemia, Acute Myeloid Leukemia in Children Trial in Tours (Biological sampling in patients, Biological sampling
Not yet recruiting
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia in Children
- Biological sampling in patients
- Biological sampling in control patients
-
Tours, France
- +2 more
Mar 17, 2023
Recurrent Chronic Lymphoid Leukemia Trial in Boston (ACY-1215, Ibrutinib, Idelalisib)
Active, not recruiting
- Recurrent Chronic Lymphoid Leukemia
- ACY-1215
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 19, 2022
Pediatric and Young Adult B-Cell Malignancies After Commercially
Not yet recruiting
- Lymphoid Leukemia
- Questionnaire for patients receiving therapy
-
Palo Alto, CaliforniaStanford University
May 9, 2023
Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Tampa (CPX-351)
Active, not recruiting
- Lymphoid Leukemia
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022
Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)
Not yet recruiting
- Philadelphia-Positive ALL
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital of Soochow University
Jul 1, 2023
ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory Trial (Tafasitamab)
Not yet recruiting
- ALL, Childhood B-Cell
- +2 more
- Tafasitamab
- (no location specified)
Nov 25, 2022
Acute Lymphoid Leukemia Trial in Seoul (Blincyto)
Not yet recruiting
- Acute Lymphoid Leukemia
-
Seoul, Gangnam-gu, Korea, Republic of
- +4 more
Apr 12, 2023
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- chimeric antigen receptor T cell
-
Beijing, Beijing, ChinaBeijing Boren Hospital
Aug 12, 2022
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
Acute Lymphoid Leukemia Trial in Philadelphia (huCART19)
Recruiting
- Acute Lymphoid Leukemia
- huCART19
-
Philadelphia, PennsylvaniaChildren's Hospital of Pennsylvania
Jul 21, 2022
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia Trial in Gainesville (Orca-Q)
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Orca-Q
-
Gainesville, FloridaUniversity of Florida
Aug 26, 2022
Acute Lymphoid Leukemia, Acute Lymphoblastic Leukemia Trial in Aurora (CD19 Directed CAR T Cell)
Not yet recruiting
- Acute Lymphoid Leukemia
- Acute Lymphoblastic Leukemia
- CD19 Directed CAR T Cell
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 12, 2022
Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), MDS (MDS) Trial in New York (other, radiation, drug)
Recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Personalized rATG (P-rATG)
- +7 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 31, 2022
Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Pediatric Non-Hodgkin Lymphoma Trial in Kuala Lumpur
Not yet recruiting
- Pediatric Acute Myeloid Leukemia
- +3 more
- eHOPE
- Usual care
-
Kuala Lumpur, Malaysia
- +1 more
Jul 7, 2022
Leukemia, Lymphoid Trial in Chengdu (blinatumomab)
Recruiting
- Leukemia, Lymphoid
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Oct 27, 2023
Bone and Joints, Brain and Nervous System, Leukemia, NOS Trial in San Francisco (GOLD Program, Treatment as usual (TAU))
Recruiting
- Bone and Joints
- +4 more
- GOLD Program
- Treatment as usual (TAU)
-
San Francisco, CaliforniaStanford Cancer Institute
Jun 8, 2022
Lymphoid Leukemia Trial in Palo Alto (Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector
Not yet recruiting
- Lymphoid Leukemia
- Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- Treg CD34+ HSPC (Orca-T)
-
Palo Alto, CaliforniaStanford Cancer Center
Aug 17, 2022
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T
Recruiting
- Non Hodgkin Lymphoma
- +2 more
- Fully human anti CD19 CAR-T Cell Dose
- +2 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022
Acute Lymphoid Leukemia Trial in Spain (ARI-0001 cells)
Recruiting
- Acute Lymphoid Leukemia
- ARI-0001 cells
-
Badalona, Barcelona, Spain
- +9 more
Feb 3, 2022
Chronic Lymphoid Leukemia in Relapse Trial in Tuebingen (Belimumab 200 MG/ML [Benlysta], standard of care)
Recruiting
- Chronic Lymphoid Leukemia in Relapse
- Belimumab 200 MG/ML [Benlysta]
- standard of care
-
Tuebingen, BW, GermanyUniversity Hospital Tuebingen, CCU Translational Immunology
Feb 2, 2022
Leukemia, Lymphoid Trial in Chengdu (blinatumomab)
Not yet recruiting
- Leukemia, Lymphoid
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Oct 3, 2023